We are actively managing our global supply chains to minimise potential disruption, and we are monitoring the situation closely. We will put the needs of patients first at all times.
At present, with the exception of specific supply disruptions as outlined below, we have adequate stock in place in Australia.
Smiths Medical Product Defect Alert for CADD Infusion System Disposables Device impacting Flolan (epoprostenol sodium) administration
GSK is aware that a Product Defect Alert has been issued by Smiths Medical in relation to specific CADD Infusion System Disposables Device Models. These device models are used in the administration of GSK’s product, Flolan (epoprostenol sodium). There is no product defect for Flolan, however supply of this medicine is impacted until April 2023.
A letter (dated 21st December, TGA ref RC-2022-RN-01489-1) was issued by Smiths Medical highlighting the nature of the issue, impacted items, proposed actions and contact details. Please contact Smiths Medical (regulatory.affairs@smiths-medical.com) for any specific information.
If you are a patient using Flolan and require further information, please contact your healthcare provider.
Please visit the TGA website for ongoing updates to supply.
For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.
